Pemigatinib for Non-Small Cell Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Non-Small Cell Lung CancerPemigatinib - Drug
Eligibility
18 - 99
All Sexes
What conditions do you have?
Select

Study Summary

This trial tests a new cancer drug, to see if it is safe and effective, in people with a certain type of lung cancer who have no other treatment options.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Treatment Effectiveness

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: Up to approximately 9 months

Month 9
Cohort A: Duration of Response (DOR)
Cohort A: Overall Response Rate (ORR)
Cohort A: Overall Survival (OS)
Cohort A: Progression-Free Survivol (PFS)
Cohort B: ORR
Number of Participants With Treatment Emergent Adverse Events (TEAEs)

Trial Safety

Trial Design

2 Treatment Groups

Cohort A: Squamous NSCLC
1 of 2
Cohort B: Non-squamous NSCLC
1 of 2

Experimental Treatment

125 Total Participants · 2 Treatment Groups

Primary Treatment: Pemigatinib · No Placebo Group · Phase 2

Cohort A: Squamous NSCLC
Drug
Experimental Group · 1 Intervention: Pemigatinib · Intervention Types: Drug
Cohort B: Non-squamous NSCLC
Drug
Experimental Group · 1 Intervention: Pemigatinib · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pemigatinib
2017
Completed Phase 2
~210

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to approximately 9 months

Who is running the clinical trial?

Incyte CorporationLead Sponsor
315 Previous Clinical Trials
46,395 Total Patients Enrolled
Luisa Veronese, MDStudy DirectorIncyte Corporation
1 Previous Clinical Trials
189 Total Patients Enrolled

Eligibility Criteria

Age 18 - 99 · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Documentation of known/likely actionable known or likely FGFR1-3 alterations.
You have a histologically or cytologically confirmed advanced or metastatic NSCLC (Stage IIIB/C or IV per the AJCC Cancer Staging Manual, 8th Edition)